A mutation in POLE predisposing to a multi-tumour phenotype by Rohlin, Anna et al.
INTERNATIONAL JOURNAL OF ONCOLOGY  45:  77-81,  2014
Abstract. Somatic mutations in the POLE gene encoding the cata-
lytic subunit of DNA polymerase ε have been found in sporadic 
colorectal cancers (CRCs) and are most likely of importance in 
tumour development and/or progression. Recently, families with 
dominantly inherited colorectal adenomas and colorectal cancer 
were shown to have a causative heterozygous germline mutation 
in the proofreading exonuclease domain of POLE. The highly 
penetrant mutation was associated with predisposition to CRC 
only and no extra-colonic tumours were observed. We have iden-
tified a mutation in a large family in which the carriers not only 
developed CRC, they also demonstrate a highly penetrant predis-
position to extra-intestinal tumours such as ovarian, endometrial 
and brain tumours. The mutation, NM_006231.2:c.1089C>A, 
p.Asn363Lys, also located in the proofreading exonuclease 
domain is directly involved in DNA binding. Theoretical predic-
tion of the amino acid substitution suggests a profound effect of 
the substrate binding capability and a more severe impairment 
of the catalytic activity compared to the previously reported 
germline mutation. A possible genotype to phenotype correla-
tion for deleterious mutations in POLE might exist that needs to 
be considered in the follow-up of mutation carriers.
Introduction
Two syndromes are associated with the major part of inherited 
colorectal cancer, hereditary non-polyposis colorectal cancer 
(HNPCC) and familial adenomatous polyposis (FAP). In Lynch 
syndrome families harbour a deleterious mutation in one of 
the mis-match repair (MMR) genes, MLH1, MSH2, MSH6 or 
PMS2, and these families constitute 15-25% of families with 
HNPCC. In the major part of families with HNPCC no disease-
causing mutations in known CRC predisposing genes can be 
found. Classical FAP is characterized by the development of 
multiple colorectal adenomas and is caused by mutations in the 
APC gene. It is today possible to detect nearly all causative muta-
tions responsible for this syndrome. However, for the majority of 
patients who develop colorectal adenomas in the range from a 
few to approximately 100, the genetic basis of disease is yet to 
be unravelled. A limited number of these patients have attenu-
ated FAP (AFAP) with less polyps and higher age at onset. In 
these cases the disease is caused by less severe mutations in the 
APC gene. Attenuated polyposis can also be caused by bi-allelic 
mutations in the MUTYH gene as seen in the recessively inher-
ited MAP syndrome (MUTYH-associated polyposis).
Recently a new CRC syndrome, polymerase proof-
reading-associated polyposis was described (1). This syndrome 
is characterized by a dominantly inherited predisposition to 
the development of a variable number of colorectal adenomas 
and carcinomas. The proofreading (exonuclease) activity of 
the genes, POLE and POLD1 (encoding the proofreading 
domain of polymerase ε and δ, respectively), are impaired by 
mutations in patients with this syndrome. The phenotypical 
expression of the disease varies; carriers of mutations in the 
POLD1 gene developed endometrial tumours besides develop-
ment of colorectal adenoma and carcinoma while the POLE 
mutation p.Leu424Val conferred a highly-penetrant predispo-
sition only to colorectal adenoma and carcinoma in carriers.
We have identified a family with an amino-acid substitu-
tion p.Asn363Lys in POLE, in the same exonuclease domain 
of polymerase ε as the p.Leu424Val substitution. In this family 
mutation carriers are affected by a broad spectrum of tumours 
in addition to CRC. The substitution has a drastic affect on 
the proofreading capacity of the polymerase and we therefore 
suggest that a genotype to phenotype correlation might exist 
for this gene.
Materials and methods
Patients. All patients have given their consent and the study has 
been approved by the local ethics committee at the University 
of Gothenburg, Sweden.
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Family member III:4 (Fig. 1) had a prophylactic colec-
tomy with ileo-rectal anastomosis (IRA) at 47 years with an 
accidental unexpected finding of CRC. She also developed a 
malign rectal tumour at 53 years. Two affected individuals in 
the family, I:1 and III:10 developed primary brain tumours, a 
glioma in one case and a giant cell glioblastoma in the other. 
Six family members >50 years of age, without sign of disease 
did not carry the mutation. Two of these individuals had normal 
barium enema at 59 (II:6) and 54 years (II:8) and they both 
reached an age of 84 years without any sign of the disease. 
Family member III:8 had normal colonoscopy at 46 years and 
member III:5 had prophylactic colectomy and IRA at 49 years 
and two normal rectoscopies after that at 54 and 58 years. 
Unfortunately family member III:7 with gastric cancer could 
not be tested due to no available material. Mutation testing 
was carried out by Sanger sequencing and/or TaqMan analyses 
on blood samples in most cases but for some individuals only 
paraffin-embedded tissue were available.
DNA extraction and mutation screening. Genomic DNA was 
extracted using the BioRobot EZ1 (Qiagen, Hilden, Germany) with 
the EZ1 DNA Blood 350 µl kit (Qiagen). DNA from adenomas, 
tumours and paraffin embedded tissues were extracted using 
QiAmp DNA microkit (Qiagen) following the manufacturer's 
recommendations. Family members III:4 and III:9 (Fig. 1) were 
screened for mutations in the known CRC-predisposing genes, 
APC, MUTYH, MLH1, MSH2, MSH6 and PMS2 using Sanger 
sequencing and MLPA (Multiplex Ligation-dependent Probe 
Amplification, MRC-Holland, Amsterdam, The Netherlands) as 
described in (2). Further details on primer sequences and MLPA 
probe kits can be obtained on request.
Affymetrix genome-wide human SNP array 6.0. The GeneChip 
6.0 platform includes about 906,600 SNP- and about 900,000 
copy-number probes, covering the whole genome with an 
average spacing of approximately 1.3 kb. Samples were 
prepared according to standard conditions (Affymetrix, Santa 
Clara, CA). Purification of PCR products were performed 
using Magnetic Beads (Agencourt Bioscience Corporation, 
Beverly, MA). Hybridization, washing and staining of arrays 
were performed as described by the supplier.
Exome capture and sequencing. DNA samples from family 
members III:1, III:4, IV:2 and IV:3 were quantified using the 
Qubit system (Life Technologies, Carlsbad, CA). DNA, were 
fragmented using the Covaris S2 Ultrasonicator (Covaris, 
Woburn, MA), where after the samples were analyzed on 
the Bioanalyzer (Agilent Technologies, Santa Clara, CA) for 
correct fragment sizes. Libraries were constructed using the 
Agilent SureSelectXT Human All Exon 50Mb library kit for 
Illumina Paired End Sequencing (v3 protocol version 1.4.1, 
Agilent Technologies) according to the manufacturer's instruc-
tion. The concentration of each library was determined using 
the Qubit and the Bioanalyzer. Whole exome sequencing was 
performed on the Illumina HiScanSQ with 2x76 bp paired 
end reads using TruSeq SBS HS-v3 clustering and sequencing 
chemistry (Illumina, San Diego, CA).
Analysis of sequencing data. Quality assessment of the 
sequence reads was performed by generating QC statistics with 
FastQC (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). 
Read alignment to the reference human genome (hg19,UCSC 
assembly, February 2009) was done using BWA (3) with default 
parameters. After removal of PCR duplicates (Picard tools, 
http://picard.sourceforge.net) and file conversion (Samtools) (4), 
quality score recalibration, indel realignment and variant calling 
were performed with the GATK package (5). Variants were 
annotated with Annovar (6) using a wide range of databases 
such as dbSNP build 135 (7), dbNSFP (8), KEGG (9), the Gene 
Ontology project (10), MITOMAP (11) and tracks from the 
UCSC (12). The targeted region of the exome analysis included 
the complete coding region of the POLE gene. Reference 
sequence used for POLE was NM_006231.2.
Data filtering. All common variants among the three affected 
individuals were filtered against one unaffected individual from 
the family. An in-house control data set (38 exomes of patients 
with different disease phenotypes), provided by Genomics Core 
facility (University of Gothenburg) was then applied for filtering 
of platform specific technical artefacts and polymorphic variants.
Analysis of the c.1089C>A, p.Asn363Lys mutation. DNA from 
blood and/or paraffin-embedded tissue from family members 
were analyzed for the presence of the mutation using Sanger 
sequencing and TaqMan and the control material was analyzed 
using TaqMan. The mutation was confirmed on a second PCR 
sample. Custom TaqMan Assay Design Tool (Life Technologies) 
was used to design the probe. The analysis was preformed 
according to the manual instructions in 96-well plates on an 
Applied Biosystems 7900HT fast real-time PCR system (Applied 
Biosystems, Foster City, CA). The analyses were carried out at 
the Genomics Core Facility at the University of Gothenburg.
Results
The first attempts to identify the genetic cause of the disease in 
the family were by screening known CRC-predisposing genes 
(including APC, MUTYH, MLH1, MSH2, MSH6 and PMS2) by 
conventional Sanger sequencing and MLPA. These analyses all 
turned out negative and further attempts to isolate a possibly 
new CRC predisposing gene were done in 2007 when a linkage 
analysis was performed with Affymetrix GeneChip Mapping 
10K Array. However, these analyses did not reveal any region 
of linkage and recently a re-analysis of the 10K array revealed 
a low SNP coverage and poor marker informativity in the 
POLE region for family members. In fact POLE maps distal 
to the most terminal chromosome 12p marker on this array 
(position Chr12:133,200,348-133,263,945; Genome map build 
GRCh37/hg19). Re-analyses of family members using an array 
with an approximately 100 times denser marker set (Affymetrix 
Genome-Wide Human SNP Array 6.0) revealed a shared 
haplotype between the flanking markers rs1051219 at position 
132,237,750 and rs2291256 at position 133,393,323, and at least 
one crossover beyond the coverage of the Affymetrix 10K array 
which explains why linkage could not be established with the 
10K array. A linkage analysis of the detected mutation using 
Array 6.0 data gives a maximum LOD=3.7, which is genome-
wide significant. Using whole-exome sequencing performed on 
four individuals in the family (Fig. 1) we identified a missense 
mutation in the POLE gene, NM_006231.2:c.1089C>A, 
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p.Asn363Lys, in affected individuals (Fig. 1). A local control 
material consisting of 642 healthy blood donors (i.e. 1284 
alleles) from the western part of Sweden was also negative 
for the mutation. The mutation is not present in the NHLBI 
GOExome Sequencing Project (ESP) (https://esp.gs.washington.
edu/drupal/) nor in dbSNP (NCBI) (http://www.ncbi.nlm.nih.
gov/SNP/). The human POLE sequence contains a synonymous 
SNP (rs146639652 C/T) at the same position with a minor allele 
frequency in Americans of European decent of 0.0001 (based 
on ESP6500). The TCGA (The Cancer Genome Atlas, http://
cancergenome.nih.gov/) data set was examined for possible 
somatic presence of the mutation in colon adenocarcinoma, 
endometrial tumours, serous cystadenocarcinoma and brain low 
grade glioma without any findings.
The substitution p.Asn363Lys has a profound effect on 
the substrate binding at the active site of the proofreading 
exonuclease domain. The structural homology of this domain 
is well conserved between species. In comparing eukaryotes 
and prokaryotes, the metal-coordinating active-site residues 
and the invariant p.Asn363 can be superimposed with a root-
mean-square deviation of 0.4 Å. A high-resolution structure 
of the human polymerase ε is lacking, but the structure of 
the yeast Saccharomyces cerevisiae polymerase δ (Pol δ also 
known as Pol3) (3IAY.pdb, Protein Data Bank, www.rcsb.org) 
and the Escherichia coli Klenow fragment (KF) with bound 
ssDNA substrate (1D8Y.pdb, Fig. 2), provides, on the atomic 
level, understanding of the pathogenic properties of the amino 
acid substitution that we report. The side chain NH2-group of 
the Asn can form a direct hydrogen bond with the 4' oxygen 
of the substrate backbone. This interaction is important for 
exonuclease activity (13). In the KF, the rate for excision 
of 3' nucleotide residues drops up to 100-fold if the corre-
sponding Asn (Asn420 in the KF) is substituted for Ala (14), 
and the exonuclease activity drops a 1,000-fold when Asn is 
replaced with Asp in the DNA polymerase of the thermophilic 
Thermococcus kodakarensis (15). These mutations emphasize 
the necessity of the precise conservation that exists in the wt 
enzyme. The Ala side chain is small and does not impose steric 
hinders. Similarly, the Asp side chain is of the same size as the 
wt Asn, but, neither Asp nor Ala nor any of the other amino 
acids (possibly with the exception of Ser) can readily form the 
required stabilizing hydrogen bond to the substrate.
The very high degree of conservation of the p.Asn363, 
strictly conserved in the exonuclease domain (Fig. 3), and the 
p.Leu424 (only replaced with Met in the KF) in the B type 
polymerases demonstrates their importance for enzyme func-
tionality. The side chains of p.Tyr362 and p.Leu424 together 
form a platform for the single-stranded primer DNA and in 
S. cerevisiae, the Leu479Ser (corresponding to p.Leu424) 
mutant completely lacks exonuclease activity (16). However, 
when the Leu is substituted for Ala in the T4 DNA polymerase, 
approximately 25% exonuclease activity is retained (17), and 
the severity of the potentially milder p.Leu424Val substitution 
is difficult to assess correctly. The difference in phenotype 
of our family with the apparently more severe p.Asn363Lys 
mutation compared to the phenotype of the family with the 
Figure 1. Pedigree of the family with the POLE c.1089C>A, p.Asn363Lys mutation. Whole-exome sequencing was performed on four individuals (III:1, III:4, IV:2 
and IV:3). The mutation was present in heterozygous form in family members indicated by a plus (+). Family members negative for the mutation are indicated by 
a minus (-).
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p.Leu424Val mutation (only CRC in carriers) can probably be 
correlated with to what extent the activity of the exonuclease 
function is perturbed in the two mutant proteins.
Family members carrying the p.Asn363Lys mutation 
demonstrate a highly penetrant predisposition not only to CRC 
but also to extra-intestinal tumours such as ovarian, endome-
trial and brain tumours. In one case a mutation carrier also 
developed pancreatic cancer at age 78 (Fig. 1, family member 
II:9). The mutation was present in heterozygous form in 12 
family members. A limited number of colorectal adenomas 
in the range resembling AFAP or MUTYH-associated 
polyposis were found in mutation carriers and several of 
them had undergone polypectomy prior to development of 
CRC. To investigate the incidence of POLE mutations in the 
population from the western part of Sweden (from where the 
family originates), 87 patients with a history of familial CRC 
or disease onset at young age were examined for mutations 
in the exonuclease domain of POLE (exons 3-14, codons 
69-491). The patients had no colorectal adenoma or a number 
of adenomas in the range between a few and approximately 
100. They had all been shown to be negative for mutations 
in either the mismatch-repair genes, MSH2, MLH1, MSH6 
and PMS2 and/or APC and MUTYH. No mutation in POLE 
was found in any of these patients, and it was concluded that 
mutations in this gene only is responsible for a minor fraction 
of inherited CRC in our region.
Two colorectal tumours, one from each of family members 
III:9 and IV:2, and also a colorectal adenoma from member 
IV:3, were examined for second hits in POLE using whole-
exome sequencing and loss of heterozygosity (LOH) of the 
wt allele was examined with microarray analyses, but no 
aberrations were identified. Second hits in POLE have been 
reported (Cancer Genome Atlas Network) (1,18-21) in some 
CRC tumours which could imply a tumour suppressor activity 
of the gene but the question whether POLE act as a classical 
tumour gene is not yet clear. Five colorectal tumours from three 
affected individuals were all microsatellite stable (MSS) which 
is in line with previous findings that tumours with mutations in 
Figure 2. Superposition of the yeast DNA polymerase (3IAY.pdb) and ssDNA substrate from the Escherichia coli DNA polymerase Klenow fragment (1D8Y.pdb) 
with the polymerase domain (blue), the double stranded DNA (brown and magenta) and the proof-reading exonuclease domain (green). The ssDNA is shown in 
yellow. Magnification of the polymerase binding to an ssDNA; The NH2-group of the Asn side chain (red), structurally equivalent to the human POLE p.Asn363, 
forms a direct hydrogen bond with the 4'oxygen of the ssDNA backbone. PyMOL (http://www.pymol.org) was used for generating the structure superposition.
Figure 3. Alignment of ortholog POLE sequences showing conservation of the p.Asn363 amino acid between species.
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POLE are MSS and are hypermutated with mutations in other 
genes involved in the classical tumorigenesis pathway (1,21).
Discussion
The family presented here has been a research subject since 
1980 due to the striking dominant inheritance of tumours and 
a clinical description of the family was published 1984 (22). 
A first report relating to the genetic cause of disease on chro-
mosomal level was published in 1989 (23). During the years 
the family has been screened for deleterious mutations in 
known CRC-predisposing genes without any findings. Exome 
sequencing finally made it possible to identify the genetic 
cause of disease in the family. The mutation is likely to have 
a profound effect on the proofreading activity of the exonu-
clease function of POLE as is shown by mutagenesis studies 
performed in microorganisms and further corroborated by the 
high degree of conservation at this amino acid location.
It has been suggested that a possible genotype to phenotype 
correlation might exist in the polymerase proofreading-asso-
ciated polyposis. Palles et al (1) reported that the mutation, 
p.Ser478Asn, in POLD1, encoding the exonuclease domain 
of polymerase δ predisposes carriers not only to colorectal 
tumours but also to endometrial cancer and possibly also to 
brain tumours. The apparent difference in tumour spectrum 
between carriers of the POLE p.Leu424Val and the POLD1 
p.Ser478Asn substitutions was unexplained and the authors 
mention that similar differences are found in Lynch syndrome 
where endometrial cancer seems to be more frequent in 
carriers of MSH6 mutations. However, the p.Asn363Lys muta-
tion reported on here clearly demonstrates that mutations in 
POLE can predispose carriers to a broad spectrum of tumours. 
When comparing the effect of the two amino acid substitutions, 
the p.Leu424Val reported (1) and the p.Asn363Lys presented 
here, it is possible to more accurately suggest that a genotype 
to phenotype correlation exist for this gene. The p.Asn363Lys 
substitution that we now report on have a more drastic effect 
on the proofreading activity which seemingly has the potential 
to initiate the development of various tumours in carriers, 
while the p.Leu424Val mutation seems to have a more limited 
effect which restricts carriers to the development of colorectal 
tumours. We thus suggest that a genotype to phenotype corre-
lation needs to be considered in the clinical follow-up of POLE 
gene mutation carriers.
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